Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.

Paolo Paganetti1, Verena Calanca, Carmela Galli

  • 1Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland.

The Journal of Cell Biology
|March 16, 2005
PubMed
Summary

Researchers developed novel single-chain antibodies to reduce amyloid beta-peptide (Abeta) production, a key factor in Alzheimer's disease (AD). These antibodies target the beta-amyloid precursor protein (APP), offering a new strategy for AD treatment and research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nucleoside-Analog Reverse-Transcriptase Inhibitors (NRTIs) Against Multiple Sclerosis: Comprehensive Review on a Possible Novel Therapeutic Approach.

Neurology international·2026
Same author

Microautophagy: current understanding of its molecular mechanisms and functions.

Autophagy reports·2026
Same author

Portioning organelles for autophagic clearance.

Autophagy·2025
Same author

CNX:FAM134B-driven ERLAD of ATZ polymers proceeds via enhanced formation of VAPA:ORP1L:RAB7 contact sites between ER and endolysosomes.

Autophagy reports·2025
Same author

Microautophagy: definition, classification, and the complexity of the underlying mechanisms.

Autophagy·2025
Same author

Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in Cancer.

Movement disorders : official journal of the Movement Disorder Society·2025

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Immunology

Background:

  • Alzheimer's disease (AD) is characterized by the accumulation of toxic amyloid beta-peptide (Abeta) in the brain.
  • Abeta is generated from the beta-amyloid precursor protein (APP) through endoproteolysis by beta- and gamma-secretases.

Purpose of the Study:

  • To establish a novel intracellular approach to regulate Abeta production using single-chain antibodies (intrabodies).
  • To investigate the efficacy of intrabodies targeting APP to inhibit Abeta generation.

Main Methods:

  • Generation of single-chain antibodies (intrabodies) targeting an epitope near the beta-secretase cleavage site of human APP.
  • Intracellular expression of intrabodies within the endoplasmic reticulum (ER) to interact with newly synthesized APP.

Related Experiment Videos

  • Tracking APP transport and assessing cleavage by secretases in the presence of intrabodies.

    • Main Results:

    • One intrabody shielded the beta-secretase cleavage site, promoting alpha-secretase cleavage and reducing Abeta generation.
    • A second intrabody with ER retention sequence triggered APP degradation, significantly decreasing Abeta production.
    • Both intrabodies demonstrated substantial inhibition of Abeta generation, with one nearly abolishing it.

    Conclusions:

    • Intrabody-based strategies targeting specific substrates like APP can effectively modulate intracellular processes relevant to diseases such as Alzheimer's.
    • This approach offers high specificity for modulating disease-related molecular mechanisms and investigating cellular events.